BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marinone C, Mestriner M. HBV disease: HBsAg carrier and occult B infection reactivation in haematological setting. Dig Liver Dis. 2011;43 Suppl 1:S49-S56. [PMID: 21195372 DOI: 10.1016/s1590-8658(10)60692-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Xu F, Zeng Z, Yan B, Fu Y, Sun Y, Yang G, Tu L, Watanabe S, Jabbour SK, Bravaccini S, Fanini F, Zhou J, Shen Y. Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study. Transl Lung Cancer Res 2021;10:1819-28. [PMID: 34012795 DOI: 10.21037/tlcr-21-79] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O, Biehl L, Cornely OA. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol 2015;94:1441-50. [PMID: 26193852 DOI: 10.1007/s00277-015-2447-3] [Cited by in Crossref: 77] [Cited by in F6Publishing: 54] [Article Influence: 11.0] [Reference Citation Analysis]
3 Liao YP, Jiang JL, Zou WY, Xu DR, Li J. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients. World J Gastroenterol 2015; 21(14): 4284-4292 [PMID: 25892880 DOI: 10.3748/wjg.v21.i14.4284] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
4 Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, Rosato V, Perna F, Pane F, Persico M. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. BMC Gastroenterol 2014;14:31. [PMID: 24533834 DOI: 10.1186/1471-230X-14-31] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
5 Xu J, Zhu H, Zhao Y, Wang X, Shen Y, Wang W, Xu F. Factors associated with hepatic dysfunction in hepatitis B-positive patients with postgastrectomy adenocarcinoma. Oncol Lett 2012;4:471-6. [PMID: 22970045 DOI: 10.3892/ol.2012.745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
6 Marignani M, Fonzo MD, Begini P, Gigante E, Deli I, Pellicelli AM, Gallina S, Santis E, Fave GD, Cox MC. ‘Les liaisons dangereuses’: Hepatitis C, Rituximab and B-cell non-Hodgkin’s lymphomas. World J Gastrointest Pharmacol Ther 2012; 3(2): 21-28 [PMID: 22577616 DOI: 10.4292/wjgpt.v3.i2.21] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Pergam SA, Mattson DK, Boeckh M. Infections in Leukemia and Hematopoietic Stem Cell Transplantation. Leukemia and Related Disorders 2012. [DOI: 10.1007/978-1-60761-565-1_12] [Reference Citation Analysis]
8 Gigante E, Deli I, Gallina S, De Santis E, Delle Fave G, Marignani M. Different hepatitis B carrier categories need different management strategies in case of immunosuppressive chemotherapeutic regimens. Annals of Oncology 2011;22:1462-1463. [DOI: 10.1093/annonc/mdr257] [Reference Citation Analysis]